Literature DB >> 7489484

Intrinsic U2AF binding is modulated by exon enhancer signals in parallel with changes in splicing activity.

Z Wang1, H M Hoffmann, P J Grabowski.   

Abstract

A functional analysis of exon replacement mutations was performed in parallel with RNA-protein binding assays to gain insight into the role of the exon in alternative and simple splicing events. These results show that constitutive exons from unrelated genes contain strong signals that promote splicing in multiple sequence contexts by enhancing 3' splice site activity. A clue to the nature of the relationship between the exon and adjacent 3' splice site is indicated by the binding properties of exon variant RNAs when tested with different biochemical preparations of the essential splicing protein, U2AF. In the context of a complete nuclear extract, U2AF binding to the 3' splice site is stimulated by the presence of an adjacent constitutive exon. In contrast, highly purified HeLa U2AF binds equivalently to the exon variants under conditions in which differential polypyrimidine tract binding is evident. These results provide support for an assisted binding model in which positive-acting signals within exons, exon enhancers, direct the binding of accessory factors, which in turn increase the intrinsic affinity of U2AF for the adjacent 3' splice site. Further support for an assisted binding model is indicated by biochemical complementation of U2AF binding and by the localization of a novel exon enhancer, which, when introduced into a weak exon, stimulates splicing activity in parallel with U2AF binding. Immunoprecipitation analysis identifies the splicing factor, SC35, as a constituent of the exon enhancer binding complex. These results are discussed in the context of current models for functional exon-bridging interactions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489484      PMCID: PMC1369055     

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  75 in total

1.  Identification of a bidirectional splicing enhancer: differential involvement of SR proteins in 5' or 3' splice site activation.

Authors:  C F Bourgeois; M Popielarz; G Hildwein; J Stevenin
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  Yeast U1 snRNP-pre-mRNA complex formation without U1snRNA-pre-mRNA base pairing.

Authors:  H Du; M Rosbash
Journal:  RNA       Date:  2001-01       Impact factor: 4.942

3.  Modulation of exon skipping by high-affinity hnRNP A1-binding sites and by intron elements that repress splice site utilization.

Authors:  M Blanchette; B Chabot
Journal:  EMBO J       Date:  1999-04-01       Impact factor: 11.598

4.  The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4.

Authors:  E Stickeler; S D Fraser; A Honig; A L Chen; S M Berget; T A Cooper
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

5.  The hnRNP A1 protein regulates HIV-1 tat splicing via a novel intron silencer element.

Authors:  T O Tange; C K Damgaard; S Guth; J Valcárcel; J Kjems
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

6.  SRp30c is a repressor of 3' splice site utilization.

Authors:  Martin J Simard; Benoit Chabot
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

Review 7.  Sorting out the complexity of SR protein functions.

Authors:  B R Graveley
Journal:  RNA       Date:  2000-09       Impact factor: 4.942

8.  Control of hnRNP A1 alternative splicing: an intron element represses use of the common 3' splice site.

Authors:  M J Simard; B Chabot
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

9.  Combinatorial control of a neuron-specific exon.

Authors:  E F Modafferi; D L Black
Journal:  RNA       Date:  1999-05       Impact factor: 4.942

10.  Roles of hnRNP A1, SR proteins, and p68 helicase in c-H-ras alternative splicing regulation.

Authors:  Sònia Guil; Renata Gattoni; Montserrat Carrascal; Joaquín Abián; James Stévenin; Montse Bach-Elias
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.